 |
Apr 28, 2005
Threshold Pharmaceuticals to Announce First Quarter 2005 Results on May 2, 2005 |
| |
REDWOOD CITY, Calif., April 28 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD - News) today announced that it will report first quarter 2005 results on Monday, May 2, 2005 after the market closes. Following the announcement, Threshold senior management will host a conference call at 4:30 p.m. Eastern Time to discuss opera...
|
|
Mar 31, 2005
Threshold Pharmaceuticals to Participate in Two Investor Conferences in April 2005 |
| |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 31, 2005--Threshold Pharmaceuticals, Inc. (Nasdaq:THLD - News) today announced that it will present at the following investor conferences in April 2005:
CIBC World Markets Annual Biotechnology and Specialty
Pharmaceuticals Conference
Threshold's President, George Tidmarsh, M...
|
|
Feb 4, 2005
Threshold Pharmaceuticals Announces Initial Public Offering |
| |
Redwood City, CA - February 4, 2005Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced today its initial public offering of 5,333,333 shares of common stock at a price of $7 per share. All of the shares are being offered by Threshold. The shares will trade on the NASDAQ National Market under the symbol "THLD".The...
|
|
Jan 18, 2005
Threshold Pharmaceuticals Appoints Alan Colowick, M.D. As Chief Medical Officer |
| |
Redwood City, CA - January 18, 2005Threshold Pharmaceuticals today announced that Alan Colowick, M.D. has been named Chief Medical Officer (CMO).From 1999 to 2005, Dr. Colowick held a variety of positions with Amgen, most recently as vice president of European Medical Affairs, where he managed a regional, cross-functi...
|
|
Dec 20, 2004
Threshold Pharmaceuticals Initiates Phase 1/2 Trial Evaluating Glufosfamide As First-Line Pancreatic Cancer Therapy |
| |
South San Francisco, California - December 20, 2004Threshold Pharmaceuticals, Inc. (www.thresholdpharm.com) announced today that it has initiated patient enrollment for a Phase 1/2 clinical trial evaluating the dosing, safety and activity of Glufosfamide in combination with gemcitabine for treating advanced solid malignancies or ...
|
|
Nov 15, 2004
Threshold Pharmaceuticals Receives FDA Fast-Track Status for Glufosfamide |
| |
South San Francisco, California - November 15, 2004Threshold Pharmaceuticals Inc. (www.thresholdpharm.com) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to one of the company's lead drug candidates, glufosfamide, for injection to treat unresectable locally advanced or metastatic pa...
|
|
Oct 13, 2004
Threshold Pharmaceuticals Appoints William A. Halter and George G. C. Parker to Board Of Directors |
| |
South San Francisco, California - October 13, 2004Threshold Pharmaceuticals, Inc. today announced the addition of William A. Halter and George G. C. Parker, Ph.D. to its board of directors.Mr. Halter has over 20 years of leadership experience in the public and private sectors. Nominated by the President and confirmed ...
|
|
Sep 13, 2004
Threshold Begins Enrollment in Phase 3 Pancreatic Cancer Clinical Trial |
| |
South San Francisco, Calif. - September 13, 2004Threshold Pharmaceuticals Inc. (www.thresholdpharm.com) announced today that it has received a Special Protocol Assessment (SPA) from the FDA for a pivotal Phase 3 clinical trial to evaluate Glufosfamide in patients with metastatic pancreatic cancer refractory to first-line treatmen...
|
|
Jun 5, 2004
Threshold Pharmaceuticals to Present Data on Glufosfamide Trial Results at 2004 ASCO Annual Meeting |
| |
South San Francisco, California - June 5, 2004Threshold Pharmaceuticals announced today that data from a Phase II glufosfamide trial in breast cancer have been accepted as the subject of a poster presentation at the 2004 Annual Meeting of The American Society of Clinical Oncology (ASCO) in New Orleans, Louisiana, June 5-8. Dr. Ge...
|
|
Mar 8, 2004
Threshold Pharmaceuticals Initiates Phase 1 Clinical Trial for 2-Deoxy-D-Glucose, a Compound Being Tested for the Treatment of Cancer |
| |
South San Francisco, California - March 8, 2004Threshold Pharmaceuticals Inc., a privately held biotechnology company, announced today the commencement of a phase 1 clinical trial of 2-deoxy-D-glucose (2DG). The trial will be carried out at the University of Miami's Sylvester Comprehensive Cancer Center (SCCC).2DG is ...
|
|
Mar 4, 2004
Threshold Pharmaceuticals Announces Appointment of Scientific Advisory Board Members |
| |
South San Francisco, California - March 4, 2004Threshold Pharmaceuticals, a privately-held pharmaceutical company focused on the development of multiple cancer drugs targeting the unique metabolic properties of tumors, has formalized its scientific advisory board with the addition of two new members. Comprised of world-renowned o...
|
|
Jan 27, 2004
Threshold Pharmaceuticals to Present at the U.S. Bancorp Piper Jaffray Annual Health Care Conference |
| |
South San Francisco, California - January 27, 2004Threshold Pharmaceuticals today announced that Barry Selick, Chief Executive Officer will present at the U.S. Bancorp Piper Jaffray Annual Health Care Conference on Wednesday, January 28, 2004 at 9:50 a.m. EST at The Pierre hotel in New York City.Threshold Pharmaceutic...
|
|
Jan 12, 2004
Threshold Pharmaceuticals Raises $41 Million in Series B Financing |
| |
South San Francisco, CA - January 12, 2004Threshold Pharmaceuticals Inc., a privately-held pharmaceutical company focused on the development of multiple cancer drugs targeting the unique metabolic properties of tumors, today announced that it has raised $41 million in a Series B financing from new and existing investors. The fina...
|
|
|
